Cargando…

Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy

Vascular endothelial growth factor receptor 2 (VEGFR2) is an attractive therapeutic target in solid malignancies due to its central role in tumor angiogenesis. Ramucirumab (Cyramza(®), LY3009806) is a human monoclonal antibody specific for VEGFR2 approved for several adult indications and currently...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lowery, Caitlin D., Blosser, Wayne, Dowless, Michele, Renschler, Matthew, Perez, Lisa V., Stephens, Jennifer, Pytowski, Bronislaw, Wasserstrom, Heather, Stancato, Louis F., Falcon, Beverly
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2019
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756863/ https://www.ncbi.nlm.nih.gov/pubmed/31565186 http://dx.doi.org/10.18632/oncotarget.27148

Ejemplares similares

LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer
por: Vakana, Eliza, et al.
Publicado: (2016)

Phenotypic Fingerprinting of Small Molecule Cell Cycle Kinase Inhibitors for Drug Discovery
por: Low, Jonathan, et al.
Publicado: (2009)

Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models
por: Li, Yanxia, et al.
Publicado: (2022)

Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation
por: Huggenberger, Reto, et al.
Publicado: (2010)

Three-Dimensional Patient-Derived In Vitro Sarcoma Models: Promising Tools for Improving Clinical Tumor Management
por: Gaebler, Manuela, et al.
Publicado: (2017)

Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies
por: Peng, Sheng-Bin, et al.
Publicado: (2016)

Anti-tumor effects of a human VEGFR-2-based DNA vaccine in mouse models
por: Xie, Ke, et al.
Publicado: (2009)

VEGFR2-targeted antibody fused with IFNαmut regulates the tumor microenvironment of colorectal cancer and exhibits potent anti-tumor and anti-metastasis activity
por: Shang, Pengzhao, et al.
Publicado: (2021)

Investigating a chimeric anti-mouse PDGFRα antibody as a radiosensitizer in primary mouse sarcomas
por: Song, Erin J., et al.
Publicado: (2019)

SAIF plays anti-angiogenesis via blocking VEGF-VEGFR2-ERK signal in tumor treatment
por: Xie, Junye, et al.
Publicado: (2023)

Low-dose anti-VEGFR2 therapy promotes anti-tumor immunity in lung adenocarcinoma by down-regulating the expression of layilin on tumor-infiltrating CD8(+)T cells
por: Yang, Biaolong, et al.
Publicado: (2022)

A Method to Assess Target Gene Involvement in Angiogenesis In Vitro and In Vivo Using Lentiviral Vectors Expressing shRNA
por: Blosser, Wayne, et al.
Publicado: (2014)

Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models
por: Huseni, Mahrukh, et al.
Publicado: (2014)

Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models
por: Huseni, Mahrukh, et al.
Publicado: (2014)

Systematic target actionability reviews of preclinical proof-of-concept papers to match targeted drugs to paediatric cancers
por: Schubert, Nil A., et al.
Publicado: (2020)

Case report: Kidney perivascular epithelioid cell tumor treated with anti-VEGFR tyrosine kinase inhibitor and MTOR inhibitor
por: Zhang, Ninggang, et al.
Publicado: (2022)

Preclinical evaluation of the anti-tumor activity of pralatrexate in high-risk neuroblastoma cells
por: Clark, Rachael A., et al.
Publicado: (2020)

Anti-tumoral efficacy of therapeutic human anti-KIR antibody (Lirilumab/BMS-986015/IPH2102) in a preclinical xenograft tumor model
por: Sola, Caroline, et al.
Publicado: (2013)

Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity in a preclinical PDAC model
por: Veinalde, Rūta, et al.
Publicado: (2023)

VEGF-dependent tumor angiogenesis requires the inverse and reciprocal regulation of VEGFR1 and VEGFR2
por: Zhang, Zhaocheng, et al.
Publicado: (2009)

Combination of EP4 antagonist and checkpoint inhibitors promotes anti-tumor effector T cells in preclinical tumor models
por: Bao, Xingfeng, et al.
Publicado: (2015)

Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma
por: Budhu, Sadna, et al.
Publicado: (2021)

First-in-human, phase I study of AK109, an anti-VEGFR2 antibody in patients with advanced or metastatic solid tumors
por: Zheng, Y., et al.
Publicado: (2023)

Vorolanib, a novel tyrosine receptor kinase receptor inhibitor with potent preclinical anti-angiogenic and anti-tumor activity
por: Liang, Chris, et al.
Publicado: (2022)

Karonudib has potent anti-tumor effects in preclinical models of B-cell lymphoma
por: Oksvold, Morten P., et al.
Publicado: (2021)

Calorie Restriction Impairs Anti-Tumor Immune Responses in an Immunogenic Preclinical Cancer Model
por: Dung, Nguyen Tien, et al.
Publicado: (2023)

Fucoxanthin administration delays occurrence of tumors in xenograft mice by colonospheres, with an anti-tumor predictor of glycine
por: Terasaki, Masaru, et al.
Publicado: (2019)

Targeting VEGFR1- and VEGFR2-expressing non-tumor cells is essential for esophageal cancer therapy
por: Xu, Wen Wen, et al.
Publicado: (2014)

Transfer learning between preclinical models and human tumors identifies a conserved NK cell activation signature in anti-CTLA-4 responsive tumors
por: Davis-Marcisak, Emily F., et al.
Publicado: (2021)

Anti-tumoral activity of single and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancers
por: Fondevila, Flavia, et al.
Publicado: (2019)

MTL-CEBPA Combined with Immunotherapy or RFA Enhances Immunological Anti-Tumor Response in Preclinical Models
por: Huang, Kai-Wen, et al.
Publicado: (2021)

Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
por: Steeghs, Neeltje, et al.
Publicado: (2009)

Improved anti-tumor immunity and efficacy upon combination of the IDO1 inhibitor GDC-0919 with anti-PD-l1 blockade versus anti-PD-l1 alone in preclinical tumor models
por: Spahn, Jessica, et al.
Publicado: (2015)

Preclinical characterization and phase I clinical trial of CT053PTSA targets MET, AXL, and VEGFR2 in patients with advanced solid tumors
por: Ma, Yu-Xiang, et al.
Publicado: (2022)

The Role of the VEGF-C/VEGFRs Axis in Tumor Progression and Therapy
por: Chen, Jui-Chieh, et al.
Publicado: (2012)

The role and significance of VEGFR2(+) regulatory T cells in tumor immunity
por: Zhu, Panrong, et al.
Publicado: (2017)

Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent
por: Jiang, Zongru, et al.
Publicado: (2020)

Targeting Anti-Angiogenic VEGF(165)b–VEGFR1 Signaling Promotes Nitric Oxide Independent Therapeutic Angiogenesis in Preclinical Peripheral Artery Disease Models
por: Kuppuswamy, Sivaraman, et al.
Publicado: (2022)

Modulation of immune cell infiltrate with sunitinib to improve anti-PD1 therapy in preclinical tumor model
por: Rayman, Patricia, et al.
Publicado: (2015)

Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma
por: Kawano, Satoshi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_eia705ivn81gv2i7q14rbfg5c9